Etretinate
From Wikipedia, the free encyclopedia
 |
|
|
Etretinate
|
|
| Systematic (IUPAC) name | |
| ethyl 9-(4-methoxy-2,3,6-trimethyl-phenyl)- 3,7-dimethyl-nona- 2,4,6,8-tetraenoate | |
| Identifiers | |
| CAS number | 54350-48-0 |
| ATC code | D05BB01 |
| PubChem | 3312 |
| DrugBank | APRD00966 |
| Chemical data | |
| Formula | C23H30O3 |
| Mol. weight | 354.483 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Etretinate (trade name Tegison®) is a medication used to treat severe psoriasis. It was removed from the United States market in 1998 and the Canadian market in 1996, due to the high risk of birth defects.
[edit] Precautions
- Etretinate is a teratogen, and may cause birth defects long after use. Therefore, etretinate should only be used if one is never to get pregnant.
- Etretinate should be avoided in children, as it may interfere with growth of bone.
[edit] Side effects
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
